Reproductive Medicine News
-
Showcase
A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). Hypothesis: The ...
-
Showcase
ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study with Letrozole, Palbociclib and Onapristone ER
Extended release Onapristone (Onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and stabilizes PR association with compressors, resulting in an antineoplastic effect when applied alone or in combination with antiestrogen therapy to breast cancer cells in vitro (1). Recent preclinical studies further suggest that onapristone adds to inhibition ...
-
Showcase
Primary Results of Onawa (Solti-1802) Trial: A Window Of Opportunity Trial Of Onapristone In Postmenopausal Women With Progesterone Receptor-Positive/Her2-Negative Early Breast Cancer
PGR is an estrogen-responsive gene and progesterone receptor (PR) expression, evaluated by immunohistochemistry (IHC), is used as a clinical biomarker of estrogen signaling and estrogen receptor (ER) functionality.1 Despite the well-studied role of PGR as mitogen and independent ER activator, anti-progestins for the treatment of BC have been poorly tested. While limited success for ...
-
Showcase
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. Because of liver enzyme elevations ...
-
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, ...
-
Onconova Therapeutics Announces Plans For A Phase 1/2a Trial Of Narazaciclib Combined With Letrozole In Endometrial Cancer, Reports Third Quarter 2022 Financial Results, And Provides A Business Update
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced plans for a Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). In addition, the Company reported its third ...
-
INTIN - Creator of a Male Sperm Analyzer and Ovulation Tester
The global fertility services market is estimated to reach $45 billion by 2027. This opens up a massive opportunity for startups to innovate in the space. One of the most innovative startups is INTIN, the creator of a male sperm analyzer called OVIEW-M, which uses the camera on a smartphone to analyze sperm counts. They are also the creators of an at-home ovulation tester that uses salvia instead ...
By INTIN Inc.
-
Heska to Acquire LightDeck Diagnostics to Invest in Manufacturing Capabilities and Accelerate Research and Development Efforts
Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics (“LightDeck”), a pioneer in innovative planar waveguide ...
-
Join us at AACC 2022
As a leading company for AI-Driven IVD equipments, Reetoo will be attending AACC (American Association for Clinical Chemistry), which will take place at the McCormick Place Convention Center in Chicago from July 26 to 28. We will bring our latest products to the exhibition as below, and look forward to meeting you at our booth #4060. RT-F600: Automatic Vaginal Secretion Analyzer ...
-
CHA Medical & Bio Group Announces Groundbreaking for Its New Cell Gene Biobank Facility
CHA Medical & Bio Group officially began construction of its Cell Gene Biobank (CGB) facility in Pangyo, South Korea. Investing over $250 million in the project, the new 710,000 ft2 site will comprise one of the world’s largest single facilities for cell and gene therapy manufacturing and advanced stem cell biobanking. The construction of the state-of-art facility is expected to be ...
-
Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for ...
-
Classification and Biological Functions of Glycoproteins
Glycoprotein is a protein containing oligosaccharide chains that are covalently linked to each other. The oligosaccharide chains are usually linked to the protein by glycosylation. Glycoproteins are commonly found in animals, plants and microorganisms, with a wide variety of species and functions. They can be classified into three categories: 1. Soluble glycoproteins, which exist in ...
-
Contraline Secures $10.7M Series A
Contraline, Inc., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has closed $10.7 million in its Series A financing. The financing round was led by MBX Capital, a venture capital firm that invests in early-stage healthcare and life sciences companies. Additional investors in Contraline include: Rhia ...
-
Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed
First in Class Insemination Treatment for Infertility LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women's healthcare, today announced the initiation and first patient treated in a pivotal trial evaluating FemaSeed, a first in class, localized directional insemination product candidate for ...
By Femasys Inc.
-
Reetoo made a wonderful appearance at CACLP
From March 28 to March 30, 2021, the 18th China International Laboratory Medicine and Blood Transfusion Instruments and Reagent Expo was successfully held at Chongqing International Expo Center. Reetoo Biotech carries 7 major types of specimen series products, including vaginal secretion detector, sperm quality analyzer, automatic chromosome microscopic image scanning system, automatic urine ...
-
Male Contraceptive Initiative Awards Grant to Contraline
Charlottesville, VA – Male Contraceptive Initiative (MCI), a private non-profit foundation, announced the award of a $200,000 grant to the medical device company Contraline, Inc. for the development of a novel vas-occlusive contraceptive device. Contraline has invented a proprietary hydrogel that is implanted into the vas deferens through a minimally invasive, outpatient procedure. The ...
-
New Data Demonstrate That Seno Medical’s Opto-Acoustic Imaging Technology Offers A Non-Invasive Approach to Differentiating Breast Cancer Molecular Subtypes
Seno Medical Instruments, Inc. (Seno Medical), the leader in new technology for breast cancer diagnosis using opto-acoustic (OA/US) imaging to differentiate benign from malignant masses, reported results of a study demonstrating that morphologic and functional OA/US features provide a non-invasive approach to helping distinguish breast cancer molecular subtypes. The data were presented on ...
-
Contraline CEO to Present at the 43rd American Society of Andrology Conference
April 22, 2018 – Charlottesville, Virginia – Kevin Eisenfrats, Co-Founder and CEO of Contraline, Inc., will be sharing the history, current-state-of-the-art, and innovation in vas-occlusive medical devices in a featured talk at the American Society of Andrology 43rd Annual Conference in Portland, Oregon. His talk, titled “The Past, Present, and Future of Vas-Occlusive Medical ...
-
DxNow, Inc. Receives FDA 510(k) Clearance for ZyMot ICSI and ZyMot Multi Sperm Separation Devices
DxNow, Inc., a privately held medical device company, announces receipt of FDA 510(k) clearance of its ZyMot™ ICSI and ZyMot™ Multi Sperm Separation Devices. DxNow is developing novel devices for use in assisted reproductive technology (ART) procedures conducted by fertility clinics and OB/GYN practices. The ZyMot devices are intended for preparing motile sperm from semen for use in ...
-
Join our live webinar on the detection of small molecules using an ultrasensitive SPRi based NanoAptasensor, on Thursday, March 24th, 2016.
During this webinar, you will learn how the combination of the X-Aptamer Selection Kit from AM Biotechnologies with HORIBA's SPRi system allows you to develop and screen aptamers from small molecules in a short period of time. In addition, we will review in detail the construct of the SPRi based NanoAptasensor, which allows you to analyze in a label-free and real time manner ultra-sensitively and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you